2nd half 2021, page-3

One obvious. One speculative based upon reports of medical progress.

The Dana Farber results will be quite positive, confirming the decision of Kazia insiders to sell none of their shares despite the stock quintupling.

And there will be a significant breakthrough in the generic application of P13K inhibitors, especially in regard to brain-localized diseases including GBM and Alzheimer's.

If the first of these forecasts is realized the stock doubles. If the second is realized the stock doubles again.

I believe I am being extremely conservative.